XANTHUS PHARMACEUTICALS, INC. EXPANDS ONCOLOGY PIPELINE WITH LATE-STAGE ORAL FLUDARABINE FROM SCHERING AG

Xanthus Pharmaceuticals, Inc., a privately held oncology drug development company, announced that the company has licensed from Schering AG the exclusive right to develop and commercialize oral fludarabine in the United States.

BioSpace (http://www.biospace.com/news_story.aspx?StoryID=31915&full=1)